Takeda Presents Results of TAK-003 in P-III (TIDES) Trial for the Prevention of Dengue at NECTM8 2022
- The P-III (TIDES) trial evaluated the 2 doses of TAK-003 (0.5ml, SC) vs PBO in a ratio (2:1) in 20,000 healthy children & adolescents ages 4 to 16yrs. for the prevention of dengue fever of any severity & due to any of the four dengue virus serotypes for 4.5yrs.
- The results showed a vaccine efficacy of 84.1% with 85.9% & 79.3% VE in seropositive & negative patients, overall VE of 61.2% against VCD with 64.2% & 53.5% VE in seropositive & negative patients. The results were consistent with prior reported results, were well tolerated with no imp. safety risks & no evidence of disease enhancement over 54mos. follow-up exploratory analysis
- TAK-003 is currently under EMA’s review for dengue disease in children & adults and select dengue-endemic countries
Ref: Businesswire | Image: Takeda
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.